Anti-proliferation effect of sorafenib in combination with 5-FU for hepatocellular carcinoma in vitro: antagonistic performance and mechanism
Li-fen DENG,Yan-hong WANG,Qing-an JIA,Zheng-gang REN,Hu-jia SHEN,Xiao-jing SUN,Jing-huan LI
DOI: https://doi.org/10.3760/cma.j.issn.1007-3418.2013.11.011
2013-01-01
Abstract:Objective To investigate the anti-cancer efficacy and mechanism of sorafenib and 5-fluorouracil (5-FU) therapy in vitro using the HCC cell line MHCCLM3.Methods The effects of somfenib and 5-FU,alone or in combination,on the proliferation of MHCCLM3 cells were evaluated by cell viability assays.Combined-effects analyses were conducted according to the median-effect principle established by Chou and Talalay.Effects on cell cycle distributions were tested by flow cytometry and expression of proteins related to the RAF/MEK/ERK and STAT3 signaling pathways and cyclinD1 were tested by western blotting.Results Sorafenib and 5-FU alone or in combination displayed significant efficacy in inhibiting proliferation of the MHCCLM3 cells,with the following inhibition rates:somfenib:46.16％ ± 2.52％,5-FU:28.67％ ± 6.16％,and sorafenib + 5-FU:22.59％ ± 6.89％.The somfenib + 5-FU combination did not provide better results than treatment with either drag alone.The combination index values of the sorafenib and 5-FU treatments were mainly greater than 1,indicating that the two agents induced antagonistic,instead of synergistic,effects on the MHCCLM3 cells.In addition,the MHCCLM3 cells were less semitive to 5-FU when administrated in combination with sorafenib,as evidenced by the half inhibitory concentration (IC50) significantly increasing from (102.86 ± 27.84) mg/L to (178.61 ± 20.73) mg/L (P =0.003).Sorafenib alone induced G1 phase arrest (increasing from 44.73％ ± 1.63％ to 65.80％ ± 0.56％; P ＜ 0.001) and significantly decreased the proportion of cells in S phase (decreasing from 46.63％ ± 0.65％ to 22.83％ ± 1.75％; P ＜ 0.01),as well as down-regulated cyclinD1 expression (0.57 ± 0.03-fold change vs.untreated control group; P ＜ 0.01).5-FU alone up-regulated cyclinD1 expression (1.45 ± 0.12-fold change vs.untreated control group; P ＜ 0.01).Moreover,somfenib alone significantly inhibited the RAF/MEK/ERK and STAT3 pathways,with the fold-changes of p-C-RAF,p-ERK1/2 and p-STAT3 being 0.56 ±0.05,0.54 ± 0.02 and 0.36 ± 0.02,respectively (allP ＜ 0.01); 5-FU alone produced no significant effects on these pathways.Conclusion Administered alone,both somfenib and 5-FU exert anti-tumoral activity on in vitro cultured HCC cells.The somfenib + 5-FU combination treatment produces antagonistic,rather than synergistic,effects.Somfenib-inhibited RAF/MEK/ERK and STAT3 signaling and cyclinD1 expression may have induced the observed G lphase arrest and S phase reduction,thereby reducing the cells' sensitivity to 5-FU.